- Reaction score
- 991
Where are the results of the Sandalore trials in the Canary Islands??? Why must everything take so f*****g long?? if it failed, they should just say it failed!!
https://www.barcelonahair2019.org/pdf/WCHR-2019-Abstract-Book.pdf
TOPICAL SANDALORE®, A SPECIFIC OR2AT4-STIMULATING ODORANT,
AMELIORATES FEMALE TELOGEN EFFLUVIUM:
RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL
F Jimenez, E López, M Bertolini 2, M Alam, C Ward 2,
J Chéret 2, G Westgate 3, F Rinaldi 4, R Paus 5
1. Mediteknia Clinic, Las Palmas; 2. Monasterium Lab, Germany; 3. Westgate Cons., Bedford, UK;
4. Giuliani S.p.A.; 5. Dept Dermatology, University of Miami, USA
Introduction & Objectives
Human hair follicles (HFs) express the olfactory
receptor OR2AT4, whose specific stimulation ex
vivo (in organ hair culture) by the synthetic sandalwood-
like odorant, Sandalore®, prolongs anagen,
and suppresses apoptosis by up-regulating intrafollicular
IGF-1 mediated signalling.
To study whether this effect of Sandalore® is clinically
relevant, we conducted a randomized, double-
blinded, placebo-controlled, prospective clinical
trial involving 60 female volunteers affected by
telogen effluvium with a defined, substantial degree
of hair shedding.
Material and Methods
Thirty patients clinically diagnosed as telogen effluvium
were randomly assigned to a verum group
applying once daily a solution containing 1% Sandalore
®, and 30 patients with telogen effluvium
were included in a placebo group that applied a solution
containing natural sandalwood oil (placebo),
which has the same odor as Sandalore® but does
not stimulate OR2AT4. The trial period consisted
of 24 weeks. The main study read-out parameters
were the degree of hair shedding, hair density,
anagen/catagen-telogen ratio (phototrichogram),
hair mass index (cross sectioned trichometry), hair
thickness, patient self-assessment questionnaire
and clinical evaluation.
Results
Sandalore® 1% ameliorated clinical signs of telogen
effluvium, namely it reduced hair shedding, increased
hair volume and increased the percentage
of anagen HFs over time significantly more than
placebo, and showed a trend towards increasing
the ratio of terminal/vellus hairs.
Hair shaft thickness and density were not affected.
Most of the anti-hair shedding effects were seen
already after 8 weeks and maintained at week 24.
Subjectively, individuals in the treatment group
were more satisfied than in the placebo group regarding
hair appearance and overall Results.
Conclusion
This clinical trial confirmed the anagen-maintaining
effects of Sandalore® seen ex vivo and provides the
first evidence that a cosmetic odorant can positively
impact on human hair growth in vivo, encouraging
the use of topical olfactotherapy with Sandalore®
as adjunct therapy of hair disorders characterized by excessive hair shedding.